Pharmaceutical - Respiratory and Pulmonary

Filter

Current filters:

Respiratory and Pulmonary

Popular Filters

51 to 75 of 313 results

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

First Ph III data on Boehringer’s fixed-dose combo tiotropium plus olodaterol in COPD

22-05-2014

German family-owned drug major Boehringer Ingelheim has presented positive results of the VIVACITO (NCTO1559116)…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and Pulmonarytiotropium

Vectura sees hefty rise in full-year 2013/14 revenues, as loss narrows

21-05-2014

Shares of UK developer of inhaled therapies Vectura gained 3.1% to 131.45 pence in early trading this…

FinancialPharmaceuticalRespiratory and PulmonaryVectura

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Ario Pharma strengthens scientific advisory board with two key appointments

Ario Pharma strengthens scientific advisory board with two key appointments

12-05-2014

UK-based biopharmaceutical company Ario Pharma has announced the appointment of Professor Peter Barnes…

BiotechnologyBoardroomPharmaceuticalRespiratory and PulmonaryUK

High medicine cost and low patient compliance are key issues in asthma treatment globally

09-05-2014

World Asthma Day (May 6) saw an uproar in UK media attention due to the National Review of Asthma Deaths…

EuropeHealthcarePharmaceuticalPricingRespiratory and PulmonaryUK

GlaxoSmithKline and Theravance’s Anoro Ellipta gains approval in EU

GlaxoSmithKline and Theravance’s Anoro Ellipta gains approval in EU

09-05-2014

The European Commission has granted marketing authorization for UK pharma giant GlaxoSmithKline and partner…

Anoro ElliptaEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

06-05-2014

Confirming strong rumors over the past week or so, German pharma major Bayer confirmed it has agreed…

AdempasBayerLicensingMerck & CoMergers & AcquisitionsPharmaceuticalResearchRespiratory and Pulmonaryvericiguat

Greer Labs debuts Oralair for the treatment of grass pollen allergy in USA

Greer Labs debuts Oralair for the treatment of grass pollen allergy in USA

06-05-2014

USA-based allergy immunotherapy products and services specialist Greer Laboratories today announced the…

Ares Life SciencesGREER LaboratoriesMarkets & MarketingOralairPharmaceuticalRespiratory and PulmonaryStallergenesUSA

US FDA approves GSK’s Incruse Ellipta for COPD

US FDA approves GSK’s Incruse Ellipta for COPD

01-05-2014

The US Food and Drug Administration has approved UK pharma major GlaxoSmithKline’s Incruse (umeclidinium)…

Chronic lower respiratory diseasesCOPDGlaxoSmithKlineIncruseIncruse ElliptaMajorMedicinePharmaceuticalPulmonologyRegulationRespiratory and PulmonaryUKUSA

Novartis’ Ultibro Breezhaler shows superior efficacy over Seretide in COPD

Novartis’ Ultibro Breezhaler shows superior efficacy over Seretide in COPD

30-04-2014

Swiss drug major Novartis today announced positive first results from the Phase III head-to-head LANTERN…

COPDEuropeHealth Medical PharmaMedicineNovartisPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySeretideUltibro Breezhaler

GSK gains EU marketing OK for Incruse for COPD; initiates tafenoquine Ph III program

GSK gains EU marketing OK for Incruse for COPD; initiates tafenoquine Ph III program

29-04-2014

UK pharma giant GlaxoSmithKline has received marketing authorization from the European Commission for…

EuropeGlaxoSmithKlineIncrusePharmaceuticalRespiratory and PulmonarytafenoquineTropical diseases

Novartis’ Onbrez shows non-inferiority to GSK’s Seretide in COPD

Novartis’ Onbrez shows non-inferiority to GSK’s Seretide in COPD

28-04-2014

Swiss drug major Novartis has announced encouraging top-line results from its Phase IV INSTEAD switch…

EuropeHealth Medical PharmaMedicineModerate COPDNovartisOnbrezPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySeretide

ALK-Abello links with Eddingpharm to accelerate growth in China

25-04-2014

Danish allergy specialist ALK-Abello and China-based specialty pharmaceutical company Eddingpharm have…

ALK AbelloAlutard SQAsia-PacificChinaEddingpharmLicensingPharmaceuticalRespiratory and Pulmonary

OPKO to buy Israel’s Inspiro, gaining rights to new drug delivery technology

18-04-2014

US biopharma company OPKO Health has entered into a definitive agreement to acquire Inspiro Medical an…

Inspiro MedicalMergers & AcquisitionsOPKO HealthPharmaceuticalRespiratory and Pulmonary

Canadian approval for GSK’s Incruse Ellipta as a treatment for COPD

17-04-2014

UK pharma giant GlaxoSmithKline says that Incruse Ellipta (umeclidinium) has received market authorization…

CanadaGlaxoSmithKlineIncruse ElliptaNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonary

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters

17-04-2014

The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

GSK faces bribery allegations in Poland

GSK faces bribery allegations in Poland

14-04-2014

UK pharma major GlaxoSmithKline is facing allegations of bribing doctors in Poland, according to the…

BBCGlaxoSmithKlineGSK regional managerLegalMajorMedicinePharmaceuticalPolandPulmonologyRespiratory and PulmonarySeretideUK

Pharmacovigilance Risk Assessment Committee April meeting highlights

Pharmacovigilance Risk Assessment Committee April meeting highlights

11-04-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) gave a recommendation…

Cardio-vascularEuropeMen's HealthNeurologicalPharmaceuticalRegulationRespiratory and Pulmonary

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

09-04-2014

US drugmaker Forest Laboratories and partner Almirall, Spain’s largest pharma company, say they have…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryUSA

Bayer’s Adempas gains EU clearance for two forms of PAH

Bayer’s Adempas gains EU clearance for two forms of PAH

31-03-2014

Following a previous positive opinion from the European Medicines Agency’s advisory committee, the…

AdempasBayerEuropePharmaceuticalRegulationRespiratory and Pulmonary

Insmed’s mixed results from Ph II trial for treatment resistant NTM lung infections

27-03-2014

US-based Insmed has reported mixed results from its Phase II clinical trial of Arikayce, for the treatment…

Inflammatory diseasesInsmedPharmaceuticalRegulationRespiratory and PulmonaryUSA

51 to 75 of 313 results

Parexel

Parexel

Back to top